Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
2022; Elsevier BV; Volume: 140; Issue: Supplement 1 Linguagem: Inglês
10.1182/blood-2022-163018
ISSN1528-0020
AutoresMartin Dreyling, Jeanette K. Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Martin Hutchings, Ulrich Mey, Jon Riise, Marek Trněný, Vibeke Vergote, Melania Celli, Ofer Shpilberg, María Gomes da Silva, Sirpa Leppä, Linmiao Jiang, Christiane Pott, Wolfram Klapper, Döndü Gözel, Christian Schmidt, Michael Unterhalt, Marco Ladetto, Eva Hoster,
Tópico(s)T-cell and Retrovirus Studies
Referência(s)